TITLE

Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer

AUTHOR(S)
XU, YIQING; METHUKU, NANDA; COIMBATORE, PRAVEENA; FITZGERALD, THERESA; HUANG, YIWU; XIAO, YING-YI; PAGALA, MURALI; GUPTA, SHACHI; SOLOMON, WILLIAM; RUBIN, PHILIP; TREANOR, JOHN; ASTROW, ALAN; MINKOFF, HOWARD; COOPER, JAY S.
PUB. DATE
January 2012
SOURCE
Oncologist;Jan2012, Vol. 17 Issue 1, p125
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. The immune response of patients who have cancer, who may be receiving immunosuppressive therapy, is generally considered to be decreased. This study aimed to evaluate the immune response of cancer patients to the 2009 influenza A (H1N1) vaccine. Patients and Methods. We conducted a prospective single site study comparing the immune response after H1N1 vaccination of healthy controls (group A), patients who had solid tumors and were taking myelosuppressive chemotherapy (group B), patients who had solid tumors and were taking nonmyelosuppressive or no treatment (group C), and patients who had hematologic malignancies (group D). Results. At 2-6 weeks after vaccination, seroconversion was observed in 80.0% of group A (95% confidence interval [CI], 65.0%- 89.7%), 72.2% of group B (95% CI, 55.9%- 84.3%), 87.0% of group C (95% CI, 72.2%- 94.7%), and 75.0% of group D (95% CI, 52.8%-89.2%) (pNS). The geometric mean titer ratio, that is, geometric mean factor increase in antibody titer after vaccination, was 12.6 (95% CI, 7.9 -19.9), 12.7 (95% CI, 7.3-22.1), 23.0 (95% CI, 13.9 -38.2), and 12.1 (95% CI, 5.3-27.9) (pNS), and the seroprotection rates were 95.5% (95% CI, 84.0%- 99.6%), 79.0% (95% CI, 63.4%-89.2%), 90.5% (95% CI, 77.4%-96.8%), and 90.0% (95% CI, 71%-98.7%) in the corresponding groups (p NS). Immune responses were robust regardless of malignancy, or time intervals between the use of myelosuppressive or immunosuppressive medications and vaccination. No participants developed clinical H1N1 infection. Conclusion. Cancer patients, whether taking myelosuppressive chemotherapy or not, are able to generate an immune response to the H1N1 vaccine similar to that of healthy controls.
ACCESSION #
71909395

 

Share

Read the Article

Courtesy of MICHIGAN ELIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics